Live feed
·
PRReleasevia Quantisnow
Black Diamond Therapeutics Inc. logo

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

ByQuantisnow·Wall Street's wire, on your screen.
BDTX· Black Diamond Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BDTX (Black Diamond Therapeutics Inc.) and more on Quantisnow.